Stock 3759 PHARMARON BEIJING CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Pharmaron Beijing Co., Ltd. Hong Kong S.E.

Equities

3759

CNE100003PG4

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:05 31/05/2024 BST 		5-day change 1st Jan Change
9.83 HKD +2.50% Intraday chart for Pharmaron Beijing Co., Ltd. -4.00% -37.86%
05-20 Pharmaron Beijing Unit to Sell Proteologix Stake to Johnson & Johnson MT
05-16 Johnson & Johnson entered into a definitive agreement to acquire Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $100 million. CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pharmaron Beijing Unit to Sell Proteologix Stake to Johnson & Johnson
Johnson & Johnson entered into a definitive agreement to acquire Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $100 million.
Pharmaron Beijing's Profit Rises 17% in 2023
Nomura Adjusts Pharmaron’s Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy
Pharmaron Beijing Posts 34% Profit Drop in Q1 as Revenue Slips 2%
Nomura Adjusts Pharmaron Beijing Co's Price Target to HK$15.41 From HK$17.99, Keeps at Buy
Pharmaron Beijing To Repurchase Shares Worth Up To 300 Million Yuan; Shares Jump 8%
Pharmaron Beijing Co., Ltd. announces an Equity Buyback for CNY 300 million worth of its shares.
Pharmaron Beijing Co., Ltd. Announces Executive Changes
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Pharmaron Beijing Co., Ltd. authorizes a Buyback Plan.
Pharmaron Partners Seven Firms to Float 2 Billion Yuan Fund
Pharmaron's 2023 Profit, Revenue Rise; Misses Estimates
Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023, Payable on 26 July 2024
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Nomura Adjusts Pharmaron Beijing’s Price Target to HK$17.99 From HK$30.92, Keeps at Buy
Pharmaron Beijing Sees Up to 14% Jump in 2023 Profit
Pharmaron Forecasts Up to 19% Rise in 2023 Attributable Profit
Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023
Pharmaron Beijing Buys Back Additional Series 2 Bonds
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 300759 Stock
  4. 3759 Stock
  5. News Pharmaron Beijing Co., Ltd.
  6. Other languages